Transplant Center Uses Cooperative Care Model

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 1
Volume 8
Issue 1

OMAHA, Nebraska-The Lied Transplant Center, located on the University of Nebraska Medical Center campus, recently had its grand opening and is expected to begin admitting patients this month for solid organ or bone marrow transplants. Its 14 levels include clinics and treatment rooms, 44 cooperative care suites, 44 Nebraska House guest suites, and four floors devoted to research. The Center takes its name from the Lied Foundation Trust, which donated $15 million toward construction.

OMAHA, Nebraska—The Lied Transplant Center, located on the University of Nebraska Medical Center campus, recently had its grand opening and is expected to begin admitting patients this month for solid organ or bone marrow transplants. Its 14 levels include clinics and treatment rooms, 44 cooperative care suites, 44 Nebraska House guest suites, and four floors devoted to research. The Center takes its name from the Lied Foundation Trust, which donated $15 million toward construction.

The Center has adopted the cooperative care model in which a patient’s caregiver (friend, spouse, parent, or relative) stays with the patient and provides basic care during treatment and recovery. Care partners assist with daily activities, monitor and assist with self-medication, and escort the patient to and from treatments. The center is said to be the first in the country to combine cooperative care, research, and education.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content